Medtronic Beheer

Beheer criteriumcontroles 3/4

De CEO Medtronic is Geoff Martha, benoemd in Apr2020, heeft een ambtstermijn van 3.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 16.85M, bestaande uit 8% salaris en 92% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.002% van de aandelen van het bedrijf, ter waarde $ 2.64M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 8.5 jaar.

Belangrijke informatie

Geoff Martha

Algemeen directeur

US$16.8m

Totale compensatie

Percentage CEO-salaris	8.0%
Dienstverband CEO	3.3yrs
Eigendom CEO	0.002%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	8.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Geoff Martha's beloning veranderd ten opzichte van Medtronic's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Apr 28 2023	n/a	n/a	US$4b
Jan 27 2023	n/a	n/a	US$4b
Oct 28 2022	n/a	n/a	US$4b
Jul 29 2022	n/a	n/a	US$5b
Apr 29 2022	n/a	n/a	US$5b
Jan 28 2022	n/a	n/a	US$5b
Oct 29 2021	n/a	n/a	US$5b
Jul 30 2021	n/a	n/a	US$4b
Apr 30 2021	US$16m	US$1m	US$4b
Jan 29 2021	n/a	n/a	US$3b
Oct 30 2020	n/a	n/a	US$4b
Jul 31 2020	n/a	n/a	US$4b
Apr 24 2020	US$6m	US$905k	US$5b
Jan 24 2020	n/a	n/a	US$5b
Oct 25 2019	n/a	n/a	US$5b
Jul 26 2019	n/a	n/a	US$4b
Apr 26 2019	US$4m	US$693k	US$5b

Compensatie versus markt: De totale vergoeding ($USD 16.85M ) Geoff } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de AR markt ($USD 5.73M ).

Compensatie versus inkomsten: De vergoeding van Geoff is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Geoff Martha (53 yo)

3.3yrs

Tenure

US$16,849,633

Compensatie

Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Chairman at Medtron...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Geoffrey Martha	Chairman of the Board & CEO	3.3yrs	US$16.85m	0.0023% $ 2.6m
Karen Parkhill	Executive VP & CFO	7.1yrs	US$7.14m	0.00025% $ 289.8k
Ivan Fong	Executive VP	1.4yrs	US$11.72m	0.00057% $ 660.8k
Robert J. ten Hoedt	Executive VP & President of Global Regions	8.5yrs	US$5.66m	0.0033% $ 3.8m
Robert White	Executive VP & President of Medical Surgical Portfolio	8.5yrs	US$6.03m	0.0012% $ 1.4m
Mark Ploof	Senior Vice President of Global Operations and Business Services	6.8yrs	geen gegevens	geen gegevens
Jennifer Kirk	Senior VP	2.1yrs	geen gegevens	0.00076% $ 881.1k
Kenneth Washington	Senior VP and Chief Technology & Innovation Officer	less than a year	geen gegevens	geen gegevens
Laura Mauri	Senior VP and Chief Scientific	1.3yrs	geen gegevens	geen gegevens
Ryan Weispfenning	VP & Head of Investor Relations	8.1yrs	geen gegevens	geen gegevens
Torod Neptune	Senior VP & Chief Communications Officer	2.5yrs	geen gegevens	geen gegevens
Sean Salmon	Executive VP & President of Cardiovascular Portfolio	no data	geen gegevens	0.0013% $ 1.5m

3.3yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MDTD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Geoffrey Martha	Chairman of the Board & CEO	3.7yrs	US$16.85m	0.0023% $ 2.6m
Scott Donnelly	Independent Director	10.5yrs	US$402.83k	0.00096% $ 1.1m
Kendall Powell	Independent Director	16.5yrs	US$350.03k	0.0014% $ 1.6m
Randall Hogan	Independent Director	8.5yrs	US$376.63k	0.0031% $ 3.6m
Richard Anderson	Independent Director	21.5yrs	US$365.03k	0.0065% $ 7.6m
Craig Arnold	Lead Independent Director	8.5yrs	US$376.43k	0.0026% $ 3.0m
Denise O'Leary	Independent Director	23.5yrs	US$370.83k	0.0053% $ 6.2m
Andrea Goldsmith	Independent Director	4.3yrs	US$353.23k	0.00032% $ 371.0k
Elizabeth Nabel	Independent Director	9.5yrs	US$382.63k	0.00088% $ 1.0m
Lidia Fonseca	Independent Director	1.1yrs	geen gegevens	geen gegevens
Kevin Lofton	Independent Director	2.8yrs	US$365.83k	0.00017% $ 197.1k

8.5yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MDTD wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.5 jaar).

Medtronic Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Medtronic plc, Annual General Meeting, Oct 17, 2024

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Recent updates

Medtronic plc Receives FDA Clearance for New Inpen App, Pending the Way for Its Smart MDI System Launch with Simplera™? CGM

CMS Grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral Renal Denervation Catheter

Medtronic plc Announces New, Long-Term Data from Its SPYRAL HTN-ON MED Clinical Trial

Medtronic plc Receives FDA Approval of Affera Mapping and Ablation System and Sphere-9 Catheter

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc Announces the Presentation of Clinical Study Results

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2025

Medtronic plc Announces Cash Dividend for Second Quarter of Fiscal Year 2025, Payable on October 11, 2024

Medtronic plc, Annual General Meeting, Oct 17, 2024

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Medtronic plc Increases Cash Dividend for the First Quarter of Fiscal Year 2025, Payable on July 12, 2024

Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic plc Raises Earnings Guidance for 2024

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd